Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T].

Pathologie-biologie - 1 Jun 2000

Mouroux M, Izopet J, Descamps D, Delaugerre C, Yvon-Groussin A, Angleraud F, Coutellier A, Bonmarchand M, Valantin M A, Matheron S, Agut H, Katlama C, Brun-Vezinet F, Calvez V

Abstract excerpt

Recently, d4T/ddI combination has been associated with the selection of thymidine analogue mutations (TAMs) in 50% of patients with a detectable viral load after 6 to 12 months of this bi-therapy (ALBI, STADI and BMS A1460 tests). We evaluated the rate of selection of the TAMs in naive patients with a viral load of > 200 copies/mL after: 6 months to 1 year of d4T/3TC bi-therapy (group 1); 1 year or more of a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lamivudine

Share to Mutation

Share to Reverse Transcriptase Inhibitors

Share to Stavudine

Share to Thymidine

Share to Zidovudine

Source

Identifiers

PMID: 10949850

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

[Conditions of "thymidine analog mutations" (TAMs) in naive patients treated with different combinations of d4T].PMID 10949850Read ↗

Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.Semantic proximity Read ↗

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.Semantic proximity Read ↗

Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.Semantic proximity Read ↗

Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.Semantic proximity Read ↗

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.Semantic proximity Read ↗

Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice.Semantic proximity Read ↗

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.Semantic proximity Read ↗

Short communication: selection of thymidine analogue resistance mutational patterns in children infected from a common HIV type 1 subtype G source.Semantic proximity Read ↗

Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.Semantic proximity Read ↗

Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group.Semantic proximity Read ↗

[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.